Skip to main content

Table 2 Outcomes by gender and treatment group

From: Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

  Women Men
  Olanzapine Haloperidol Olanzapine Haloperidol
Outcome measure Baseline Endpoint Baseline Endpoint Baseline Endpoint Baseline Endpoint
Core symptoms         
   BPRS positive 10.1 (4.0) 6.5 (4.8) 9.9 (4.3) 6.9 (4.4) 10.3 (4.1) 7.0 (4.6) 10.7 (4.0) 8.0 (4.6)
   BPRS negative* 6.6 (3.3) 4.4 (3.1) 6.8 (3.4) 5.5 (3.3) 6.7 (3.2) 4.8 (2.9) 6.8 (3.5) 5.5 (3.2)
Depressive symptoms         
   MADRS* 17.8 (9.6) 11.0 (9.3) 16.1 (8.6) 13.5 (10.7) 16.0 (8.4) 10.5 (7.7) 17.0 (8.7) 13.7 (9.4)
   BPRS anxiety & depression* 8.1 (3.8) 5.0 (4.0) 7.8 (4.1) 6.0 (4.3) 7.1 (3.7) 4.5 (3.6) 7.7 (3.9) 5.7 (3.9)
Functioning         
   SF-36 mental component* 34.7 (13.1) 41.8 (12.1) 34.2 (12.4) 36.5 (13.0) 34.6 (12.4) 40.6 (12.0) 34.7 (11.7) 37.8 (12.3)
   SF-36 physical component* 41.3 (14.3) 45.0 (13.9) 41.9 (13.5) 42.1 (13.8) 44.7 (12.2) 48.7 (11.6) 43.9 (13.2) 45.4 (13.1)
Weight         
   Weight, kg* 68.9 (15.5) 70.5 (15.8) 72.6 (17.8) 72.4 (17.6) 80.3 (15.9) 82.5 (16.2) 80.7 (17.1) 81.0 (17.4)
   BMI* 26.1 (5.4) 26.7 (5.5) 27.2 (6.6) 27.1 (6.5) 25.8 (4.8) 26.5 (4.9) 25.7 (5.0) 25.8 (5.0)
  1. * Therapy effect (p < .05), reflecting significant differences between olanzapine and haloperidol-treated patients at baseline.
  2. Gender effect (p < .05), reflecting significant differences between women and men on weight parameters within each treatment group at baseline, and between women and men when combined baseline values across treatment groups.